FDA
-
-
-
-
-
-
-
Aduro Biotech Reports Third Quarter 2017 Financial Results
-
-
-
-
-
-
-
Aduro Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Previously Treated Malignant Pleural
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

